NCT07663747
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07663747
Title Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC (FIDELIO)
Acronym FIDELIO
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD


No variant requirements are available.